The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Name: The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Published: 2023
License: Public Domain

Zhejiang Cancer Hospital · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

breast-neoplasms

breast neoplasms, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Related documents